MORE►
Panna Sharma
Who Made This Year’s AI 75 List? Meet the North Texans Leading the Pack in Artificial Intelligence
by Glenn Hunter | Apr 30, 2025
Dallas Innovates, in partnership with the Dallas Regional Chamber, once again is recognizing the most innovative leaders in AI in Dallas-Fort Worth. From visionaries and mavericks to transformers and academics, AI 75's class of 2025 are the AI pacesetters you need to know now.
by Glenn Hunter |
May 2, 2024
Dallas Innovates, the Dallas Regional Chamber, and Dallas AI have teamed up to launch the inaugural AI 75 list. The 2024 program honors the most significant people in AI in DFW in seven categories—the visionaries, creators, and influencers you need to know.
MORE►
by Lance Murray |
Jan 19, 2024
Marc Chamberlain, M.D., has been appointed as the Chief Medical Officer at Starlight Therapeutics.
Starlight Therapeutics is a Dallas-based Lantern Pharma subsidiary focused exclusively on the clinical development of therapies for central nervous system and brain cancers with limited or no effective therapeutic options.
In his role as CMO, Chamberlain will oversee the company’s upcoming clinical trials focused on several serious and complex brain-related conditions: glioblastoma and other high-grade gliomas (aggressive types of brain tumor), brain metastases in adults (secondary brain tumors originating from cancer elsewhere in the body), and two types of pediatric brain tumors — atypical teratoid rhabdoid tumors (ATRT) and diffuse intrinsic pontine glioma (DIPG)....
MORE►
by Lance Murray |
May 2, 2023
The "blood-brain barrier" acts like a highly selective firewall, preventing an estimated 98% of drugs from entering the brain—making it a major hurdle in the development of brain and central nervous system drugs. Lantern Pharma has recently developed what it calls "highly accurate AI algorithms" to predict the ability of a drug or compound to pass through the barrier.
MORE►
Lantern Pharma CEO Panna Sharma [Courtesy: Lantern Pharma]
Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise
by Quincy Preston | Dec 22, 2022
The Dallas-based biopharmaceutical company expects to begin testing the drug candidate in a “first in human” trial in mid-2023. The drug was developed using the publicly traded company’s AI/ML drug development platform.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
MORE►
by Bella Pinera |
Aug 3, 2021
Panna Sharma has had a hand in four IPOs. The latest was finalized during the middle of COVID for his clinical stage biopharmaceutical oncology firm, Lantern Pharma. Now, he shares the phases to transforming a young private company into the next public success story.
MORE►
by Lance Murray |
Oct 7, 2019
This alum of Dallas startup accelerator Health Wildcatters is working with the National Cancer Institute's Developmental Therapeutics Branch on precision research and treatments.
MORE►
